BiotechTube

Remimazolam Tosilate for Injection

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

General Anesthesia and Bronchoscopy Sedation

Conditions

General Anesthesia and Bronchoscopy Sedation

Trial Timeline

Aug 18, 2022 → Jun 21, 2024

NCT ID
NCT05549791

About Remimazolam Tosilate for Injection

Remimazolam Tosilate for Injection is a pre-clinical stage product being developed by Jiangsu Hengrui Medicine for General Anesthesia and Bronchoscopy Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT05549791. Target conditions include General Anesthesia and Bronchoscopy Sedation.

What happened to similar drugs?

14 of 20 similar drugs in General Anesthesia and Bronchoscopy Sedation were approved

Approved (14) Terminated (3) Active (5)
✅Duloxetine + PlaceboEli LillyApproved
✅IxekizumabEli LillyApproved
✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
✅EscitalopramAbbVieApproved
✅QuetiapineAstraZenecaApproved
✅Sugammadex + PlaceboMerckApproved
✅Alprazolam (Xanax) + PlaceboRocheApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05549791Pre-clinicalCompleted
NCT05254366Pre-clinicalCompleted

Competing Products

20 competing products in General Anesthesia and Bronchoscopy Sedation

See all competitors
ProductCompanyStageHype Score
atomoxetine + placeboEli LillyPhase 2/3
38
SatralizumabChugai PharmaceuticalPhase 3
32
PerampanelEisaiPre-clinical
26
Perampanel + Placebo comparatorEisaiPhase 3
40
zonisamideEisaiPre-clinical
26
FycompaEisaiPre-clinical
26
FycompaEisaiPre-clinical
26
PerampanelEisaiPhase 3
40
PerampanelEisaiPre-clinical
26
CenobamateOno PharmaceuticalPhase 3
47
Duloxetine + PlaceboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyApproved
43
IxekizumabEli LillyApproved
43
eszopiclone + eszopiclone + PlaceboSumitomo PharmaPhase 2
35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
43
HR020602 injection + fentanyl injection ； remifentanil injectionJiangsu Hengrui MedicinePhase 2
35
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 2
35
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)AbbViePhase 2
42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/dayAbbViePhase 2
27
ABBV-932 + PlaceboAbbViePhase 1
29